1. pregnant or breast-feeding. 2. participants who have been administered covid-19 vaccine prior to the inclusion or have a planned vaccination during the duration of the study. 3. a positive covid-19 result (pcr or antigen test) within 8 days of screening. 4. presence of typical covid-19 symptoms (fever \>38°c, spo2 below 93%, dyspnoea, difficulty breathing, chills, repeated shaking with chills, ageusia, anosmia, cough, myalgia, headache) in the past 48 hours prior to screening. 5. hypersensitivity to any component of ivermectin. 6. participants who have been administered ivermectin within 30 days prior to screening. 7. participation in another interventional trial within the last 30 days or 5 half-lives of the imp of the other trial, whichever comes first. 8. participants with gastrointestinal erosions and ulcers (e.g. erosive esophagitis, stomach ulcers, ulcerative colitis etc.). 9. history of neurotoxicity with ivermectin or other para-glycoprotein (p-gp) substrates or inhibitors. 10. current use of monoclonal antibodies for the treatment of covid-19.

1. pregnant or breast-feeding. 2. participants who have been administered covid-19 vaccine prior to the inclusion or have a planned vaccination during the duration of the study. 3. a positive covid-19 result (pcr or antigen test) within 8 days of screening. 4. presence of typical covid-19 symptoms (fever \>38°c, spo2 below 93%, dyspnoea, difficulty breathing, chills, repeated shaking with chills, ageusia, anosmia, cough, myalgia, headache) in the past 48 hours prior to screening. 5. hypersensitivity to any component of ivermectin. 6. participants who have been administered ivermectin within 30 days prior to screening. 7. participation in another interventional trial within the last 30 days or 5 half-lives of the imp of the other trial, whichever comes first. 8. participants with gastrointestinal erosions and ulcers (e.g. erosive esophagitis, stomach ulcers, ulcerative colitis etc.). 9. history of neurotoxicity with ivermectin or other para-glycoprotein (p-gp) substrates or inhibitors. 10. current use of monoclonal antibodies for the treatment of covid-19.

pregnant or breast-feeding. participants who have been administered covid-19 vaccine prior to the inclusion or have a planned vaccination during the duration of the study. a positive covid-19 result (pcr or antigen test) within 8 days of screening. presence of typical covid-19 symptoms (fever >38°c, spo2 below 93%, dyspnoea, difficulty breathing, chills, repeated shaking with chills, ageusia, anosmia, cough, myalgia, headache) in the past 48 hours prior to screening. hypersensitivity to any component of ivermectin. participants who have been administered ivermectin within 30 days prior to screening. participation in another interventional trial within the last 30 days or 5 half-lives of the imp of the other trial, whichever comes first. participants with gastrointestinal erosions and ulcers (e.g. erosive esophagitis, stomach ulcers, ulcerative colitis etc.). history of neurotoxicity with ivermectin or other para-glycoprotein (p-gp) substrates or inhibitors. current use of monoclonal antibodies for the treatment of covid-19.

pregnant or breast-feeding. participants who have been administered covid-19 vaccine prior to the inclusion or have a planned vaccination during the duration of the study. a positive covid-19 result (pcr or antigen test) within 8 days of screening. presence of typical covid-19 symptoms (fever >38°c, spo2 below 93%, dyspnoea, difficulty breathing, chills, repeated shaking with chills, ageusia, anosmia, cough, myalgia, headache) in the past 48 hours prior to screening. hypersensitivity to any component of ivermectin. participants who have been administered ivermectin within 30 days prior to screening. participation in another interventional trial within the last 30 days or 5 half-lives of the imp of the other trial, whichever comes first. participants with gastrointestinal erosions and ulcers (e.g. erosive esophagitis, stomach ulcers, ulcerative colitis etc.). history of neurotoxicity with ivermectin or other para-glycoprotein (p-gp) substrates or inhibitors. current use of monoclonal antibodies for the treatment of covid-19.